Ciprocopan's China PNH Approval Challenges Bleak European Precedent for Factor B Inhibitor Class

China Approves Nuvectis' Oral Ciprocopan for Treatment-Naive PNH

Nuvectis Pharma announced that its once-daily oral complement Factor B inhibitor, ciprocopan (NXP100), has received marketing approval from China's National Medicinal Products Administration (NMPA) for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients previously untreated with complement inhibitors. This marks the world's first approval for a once-daily oral Complement Factor B inhibitor, offering a new, effective, safe, and convenient treatment option for PNH patients. The approval is based on robust efficacy and safety data from a broad clinical development program, including a Phase 3 study demonstrating superiority over eculizumab.

• Ciprocopan is the first global approval of a once-daily, orally administered Complement Factor B inhibitor, providing a significant convenience advantage for patients requiring continuous, life-long treatment for PNH. This positions ciprocopan to potentially secure a meaningful share in the multi-billion-dollar PNH market, with expectations for Factor B inhibitors to become a leading class.
• The approval was primarily driven by a head-to-head Phase 3 study comparing ciprocopan to Soliris (eculizumab) in treatment-naive PNH patients. Ciprocopan met all primary and secondary endpoints, demonstrating superiority with 59.5% of patients reaching a hemoglobin target of 12 g/dL (vs. 8.3% for eculizumab), an approximate 5.0 g/dL hemoglobin increase from baseline (vs. 2.2 g/dL), and 94.6% not requiring transfusions (vs. 69.4%). The study also confirmed a favorable safety profile, with no adverse events leading to treatment discontinuation.
• Unlike terminal complement inhibitors, ciprocopan's Factor B inhibition selectively blocks the alternative pathway amplification while preserving the classical and lectin pathways. This mechanism is designed to provide comprehensive control of both intravascular and extravascular hemolysis, leading to improved efficacy over C5 inhibitors. Beyond PNH, ciprocopan is being explored for its potential in other complement-mediated diseases, leveraging its oral, once-daily convenience.

Why New Oral Options are Crucial for PNH Patients

Current PNH management, while transformative since the introduction of complement inhibitors, continues to fall short of fully normalizing patient outcomes. Persistent anemia, infusion-related burden, and access disparities remain significant barriers to optimal disease control, underscoring the rationale for continued innovation—including oral treatment options.

• Incomplete hematologic response with C5 inhibitors: Despite effective blockade of intravascular hemolysis, approximately 70% of patients treated with eculizumab or ravulizumab remain anemic due to underlying bone marrow failure and extravascular hemolysis driven by C3 deposition—an issue standard C5 inhibition cannot address.

• Treatment burden and evidence gaps: Eculizumab requires biweekly infusions, imposing a substantial logistical and quality-of-life burden on patients; notably, only one randomized, placebo-controlled trial has ever been conducted for eculizumab in PNH, leaving important gaps in the evidence base. Therapy costs also remain very high.

• Breakthrough hemolysis risk with proximal inhibitors: Newer proximal complement inhibitors (targeting C3, factor D, or factor B) offer improved anemia control by addressing both intravascular and extravascular hemolysis, but carry a risk of breakthrough hemolysis under complement-amplifying conditions (e.g., infection, surgery, pregnancy). Long-term real-world safety and infection data for these agents remain limited.

• Access and treatment persistence challenges: Geographic and healthcare system disparities significantly affect care delivery—for example, in Brazil, mean time to treatment initiation was 172.9 days, with patients traveling an average of 87.5 km for eculizumab infusions. Non-persistence rates ranged from 21.2% to 61.0% depending on methodology, driven by limited disease awareness, travel distances, and long waiting times.

• Regional healthcare inequities affecting diagnosis: Countries with higher healthcare system quality scores report higher PNH incidence estimates than those with lower scores, suggesting substantial underdiagnosis and unequal access to care in lower-resourced regions—highlighting a need for strengthened healthcare infrastructure globally.

• Historical disease burden without adequate control: Data from a 2000–2009 Chinese cohort illustrate the consequences of suboptimal management, with complications including infections (30.0%), thrombotic events (8.6%), progression to MDS/AML (5.7%), and mortality (17.1%)—underscoring the stakes of incomplete disease control and the continued need for therapies that more comprehensively address both hemolysis and its downstream complications.

Ciprocopan's Head-to-Head Advantage in Treatment-Naive PNH

Investigational proximal complement inhibitors are demonstrating significant advantages over standard C5-inhibiting therapies by addressing both intravascular and extravascular hemolysis. The oral Factor B inhibitor iptacopan, evaluated in the APPLY-PNH and APPOINT-PNH trials, showed substantial clinical benefits. In the APPLY-PNH study, 86% of patients switching from an anti-C5 inhibitor to iptacopan achieved a hemoglobin increase of ≥2 g/dL at 48 weeks. Similarly, in the APPOINT-PNH trial for complement-inhibitor-naïve patients, 97% achieved this endpoint. These improvements were accompanied by high rates of transfusion avoidance and a manageable safety profile, with headache and COVID-19 as the most common adverse events and no discontinuations due to treatment-emergent adverse events. Real-world data for pegcetacoplan, a C3 inhibitor, corroborates the benefits of this upstream mechanism, showing significant hemoglobin improvements, reduced transfusion dependence, and a drop in breakthrough hemolysis from 34.4% to 9.4% after six months.

Concurrently, innovation within the C5 inhibitor class is focused on reducing treatment burden and optimizing outcomes. Ravulizumab, a long-acting C5 inhibitor, offers an extended dosing interval of every 4-8 weeks, a significant improvement over eculizumab's bi-weekly infusions, thereby enhancing patient quality of life. The PNH Study 301 demonstrated that ravulizumab provides equivalent efficacy to eculizumab, with 51.2% of ravulizumab patients meeting all composite endpoint thresholds compared to 41.3% of eculizumab patients. Furthermore, the novel anti-C5 monoclonal antibody crovalimab has shown non-inferiority to eculizumab in the COMMODORE 2 trial, achieving comparable rates of hemolysis control (88.3% vs. 86.8%) and transfusion avoidance. Notably, crovalimab demonstrated a greater improvement in FACIT-Fatigue scores, suggesting a potential advantage in patient-reported outcomes.

Ciprocopan's Broader Therapeutic Potential in Complement-Mediated Diseases

While the query refers to "Ciprocopan," the literature describes clinical development for the oral Factor B inhibitor iptacopan. Beyond its use in Paroxysmal Nocturnal Hemoglobinuria (PNH), iptacopan is being investigated across a range of complement-mediated diseases, primarily through randomized, placebo-controlled trials for major indications and case studies for rarer conditions.

• IgA Nephropathy (IgAN): The Phase 3 APPLAUSE-IgAN trial was a randomized, double-blind, placebo-controlled study evaluating oral iptacopan (200 mg twice daily) against placebo. The intervention demonstrated a significant reduction in proteinuria and a slower rate of eGFR decline over 24 months compared to placebo.

• C3 Glomerulopathy (C3G): Iptacopan is FDA-approved for C3G, a decision supported by the APPEAR-C3G trial. This was a Phase 3, randomized, double-blind, placebo-controlled study assessing the efficacy of iptacopan 200 mg twice daily versus placebo, with a primary objective of reducing proteinuria.

• Immune Thrombocytopenia (ITP): Iptacopan is in late-stage clinical development for ITP, with ongoing Phase 2 and 3 studies. These trials are primarily recruiting heavily pretreated or otherwise refractory patients, evaluating a therapeutic mechanism not targeted by existing approved agents.

• Other Hematologic and Transplant-Related Conditions: Evidence from case reports and small series points to broader utility. In Transplantation-Associated Thrombotic Microangiopathy (TA-TMA), a single-arm case study of oral iptacopan (200 mg twice daily) led to significant clinical and biochemical recovery. In refractory Autoimmune Hemolytic Anemia (AIHA), iptacopan used in combination with standard immunosuppression resulted in rapid improvement in hemoglobin levels and reduction in hemolysis markers.